University of Phoenix Academic and Environmental Science Program Leaders Co-Author Study Exploring Role of Virtual Field Experiences
'The creation of place-based, immersive learning experiences grounded in educational theory addresses a gap in natural science education,' said Gielstra. 'Many scientists who teach may not have formal training in learning theory, which can limit their ability to fully support student learning. By integrating these pedagogical tools with emerging technologies, we hope to help bridge that gap, empowering students to better understand environmental challenges and collaborate effectively across disciplines to tackle them.'
The study introduces a theory-informed virtual learning environment (VLE) that uses 360-degree photography, historical imagery, and scientific field data to simulate a field trip to beaver pond ecosystems in Glacier National Park. The VLE is designed to support online learners in environmental science, geography, and landscape architecture by providing an interactive, place-based learning experience. The article introduces the researchers' philosophical framework Translating Research in Environmental Education (TREE), a model developed to bring teachings from seminal learning theories into immersive, online learning environments.
'In our Environmental Science program, TREE helps us understand our students, create meaningful opportunities for them, and guides everything we do as we reimagine how students engage with complex ecological systems and environmental education,' Kelly states.
Key features of the study include:
A virtual field trip that allows students to explore the geomorphic and ecological influence of beavers as ecosystem engineers.
Integration of educational frameworks such as TECCUPD, TREE-PG, and the VRUI model to guide VLE design and evaluation.
Use of the Normalized Difference Water Index (NDWI) to help students analyze surface water conditions and landscape change.
A new evaluation tool, the TREE-PG Implementation Prioritization Scale (TIPS), to assess the fidelity of learning theory in virtual environments.
The study found that the VLE design supported spatial thinking skills and a deeper understanding of how beaver activity contributes to climate adaptation strategies through water retention and landscape modification.
This research contributes to the growing field of virtual field-based education and offers a replicable model for educators seeking to enhance science literacy and environmental awareness in online classrooms.
Kelly is a published researcher with more nearly 20 years of experience in science and math education. Her expertise is in translating STEM education research into practice at institutions of higher education. Kelly earned a doctorate in Curriculum and Instruction with a specialization in Science Education and a master's degree in Materials Science and Engineering from Arizona State University. Her undergraduate degree is in Physics and Chemistry from California State University, San Marcos.
Gielstra is a biogeographer, course designer and faculty for the College of General Studies Environmental Science program with research interests in human and environmental connections, geography, polar, mountain, and riparian environments. Gielstra's research work includes the use of technologies to engage K-12 learners in geoscience education through virtual reality, and they serve as a team member and content contributor to GeoEPIC. Gielstra earned a doctorate in geography from Texas A&M University and holds a Master of Science in Environmental Studies from Medical University of South Carolina and Bachelor of Science in Biology from Coastal Carolina University.
Oberding is a coastal ecologist, course designer and faculty for the College of General Studies Environmental Science program. His work has taken him from the UNESCO world heritage site of HaLong Bay in VietNam to the Permian oilfield of New Mexico, and his research interests are in the fields of hydrology, mariculture, coral ecology, and environmental remediation. He earned a doctorate in Natural Resource and Environmental Management from University of Hawaii at Manoa and holds a Master of Science in Mariculture from Texas A&M University – Corpus Christi, and a Bachelor of Science in biology from The University of New Mexico.
Kelly, Gielstra and Oberding previously authored a University of Phoenix white paper about curriculum to careers programmatic mapping which was published as an article in Industry and Higher Education.
.
University of Phoenix innovates to help working adults enhance their careers and develop skills in a rapidly changing world. Flexible schedules, relevant courses, interactive learning, skills-mapped curriculum for our bachelor's and master's degree programs and a Career Services for Life® commitment help students more effectively pursue career and personal aspirations while balancing their busy lives. For more information, visit phoenix.edu.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
22 minutes ago
- Business Wire
New Irish Healthtech Firm Phyxiom Set to Transform Asthma and COPD Management
DUBLIN--(BUSINESS WIRE)-- Phyxiom, a pioneering digital healthcare company, today announced its official launch, bringing transformative technology developed through extensive clinical research led by globally recognised respiratory specialist, Professor Richard Costello (RCSI University of Medicine and Health Sciences and Beaumont Hospital). Built upon groundbreaking studies published in Lancet Respiratory Medicine and validated by health economists, Phyxiom's platform provides clinicians with precise, real-time data to significantly enhance asthma and Chronic Obstructive Pulmonary Disease (COPD) management. Co-founded by experienced tech executive Grace O'Donnell as Chief Executive Officer and healthcare professional Elaine Mac Hale as Clinical Operations Director, along with Prof Costello, Phyxiom is a spin-out company from RCSI. Based on a strong foundational IP portfolio developed under an Enterprise Ireland (EI) Commercialisation Fund award the company has recently achieved EI High Potential Start- Up (HPSU) status. O'Donnell and Mac Hale lead Phyxiom's day-to-day operations, driving forward its mission to revolutionise respiratory healthcare through advanced digital solutions. Professor Richard Costello, Chief Medical Officer at Phyxiom and Professor of Respiratory Medicine at RCSI, explained the science behind the innovation: 'Our research, spanning over a decade, has conclusively demonstrated that digitally-informed treatment significantly reduces medication use, prevents unnecessary hospitalisations, and ultimately lowers healthcare costs. By providing clinicians with objective, real-time insights into lung function and medication adherence, Phyxiom fundamentally improves diagnosis accuracy and treatment outcomes.' Phyxiom's technology is already operational across 13 Health Service Executive (HSE) asthma clinics in Ireland, processing nearly 350 patients to date, with plans to expand further and engage Irish private health insurers in 2025. Grace O'Donnell, CEO, said: 'Elaine and I are incredibly proud to lead this exciting RCSI spin-out company into the commercial market. We are passionate about using Richard's groundbreaking research as the foundation to deliver transformative, patient-centric healthcare solutions, significantly improving quality of life for patients suffering from uncontrolled asthma and COPD.' Elaine Mac Hale, Clinical Operations Director, added: 'Phyxiom seamlessly integrates into existing healthcare systems, ensuring minimal disruption to clinicians' workflows. Our evidence-based approach empowers healthcare providers with the insights needed to deliver personalised, effective, and efficient patient care.' Following its successful Irish rollout, Phyxiom is expanding into the UK market in H1 2026 and plans a US launch in 2027, supported by established partnerships and integration with leading electronic health record systems. Phyxiom's launch marks a significant milestone in Ireland's healthtech landscape, highlighting Irish innovation on the global healthcare stage. Those interested in learning more about Phyxiom, can visit the website here: About RCSI University of Medicine and Health Sciences RCSI University of Medicine and Health Sciences is ranked first in the world for its contribution to UN Sustainable Development Goal 3, Good Health and Well-being, in the Times Higher Education (THE) University Impact Rankings 2025. Founded in 1784 as the Royal College of Surgeons in Ireland with responsibility for training surgeons in Ireland, today RCSI is an innovative, not-for-profit, international university exclusively focused on driving improvements in human health worldwide through education, research and engagement. RCSI is among the top 300 universities worldwide in the World University Rankings (2025) and has been awarded Athena Swan Bronze accreditation for positive gender practice in higher education. In 2026, RCSI will open a new public engagement space, dedicated to health and well-being, at 118 St Stephen's Green in Dublin city centre. The space is designed to engage the public in dialogue about living longer, healthier and happier lives through dynamic events and exhibitions. Our aim is to bridge the gap between health sciences research, professional expertise, and public understanding, empowering people to make informed decisions about their health. Visit the RCSI MyHealth Expert Directory to find the details of our experts across a range of healthcare issues and concerns. Recognising their responsibility to share their knowledge and discoveries to empower people with information that leads them to better health, these clinicians and researchers are willing to engage with the media in their area of expertise.
Business Wire
2 hours ago
- Business Wire
Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2025. Recent Business Highlights Soft Tissue Ablation Expanded the pilot program for the nsPFA Percutaneous Electrode for soft tissue ablation. Treated over 140 Benign Thyroid Nodule patients to date across multiple pilot program centers. Identified five sites to participate in a post-market study of the treatment of benign thyroid disease, with plans to commence enrollment in Q3 upon receipt of IRB approvals. Surgical AF Ablation Submitted FDA IDE application, including the pivotal study protocol, to support a premarket approval (PMA) application for the treatment of atrial fibrillation (AF) and remain on track to commence the IDE pivotal study in the next few months. Treated 40 patients to date and generated positive clinical outcomes, as indicated by follow up remapping procedures, as part of the nsPFA Cardiac Surgery System multi-center, first-in-human AF feasibility study in Europe. Endocardial Catheter AF Ablation Submitted FDA IDE application, including the pivotal study protocol, and remain on track to commence the IDE pivotal study in the next few months. Observed improved procedure times since last presented at the Heart Rhythm Society 2025 Meeting in April. Treated over 140 total patients with the nsPFA 360° catheter to date as part of the multi-center, first-in-human AF study in Europe. 'We are advancing the top priorities established at the beginning of 2025 for each of our three market development programs,' said Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences. 'I am delighted to announce that we have expanded the pilot program for the Percutaneous Electrode for soft tissue ablation, submitted our IDE for both the cardiac surgical clamp and nsPFA 360° catheter, all while continuing to treat more patients and generate positive clinical outcomes with our cardiac devices in their respective feasibility studies in Europe. These achievements further reinforce the transformational potential of nsPFA energy for treating benign thyroid disease, AF and additional diseases in the future.' Second Quarter 2025 Financial Results Total GAAP costs and expenses, representing research and development and general and administrative expenses, for the three months ended June 30, 2025, were $20.3 million, an increase of $8.5 million compared to $11.7 million in the prior year period. The increase was primarily driven by administrative expenses related to the expanding organization to support advancement of the nsPFA device clinical trials and commercialization, and non-cash stock-based compensation and other compensation. Non-GAAP costs and expenses for the three months ended June 30, 2025, were $14.8 million, an increase of $5.4 million compared to $9.4 million in the prior year period. GAAP net loss for the three months ended June 30, 2025 was ($19.2) million compared to ($11.4) million for the three months ended June 30, 2024. Non-GAAP net loss for the three months ended June 30, 2025 was ($13.7) million compared to ($9.0) million for the three months ended June 30, 2024. Cash and cash equivalents totaled $106.3 million as of June 30, 2025, compared to $26.2 million as of June 30, 2024 and $119.3 million as of March 31, 2025. Cash used in operating activities in the second quarter of 2025 totaled $12.8 million, compared to $8.4 million used in the same period in the prior year, and $13.5 million used in the first quarter of 2025. Reconciliations of GAAP to Non-GAAP cost and expenses and net loss have been provided in the tables following the financial statements in this press release. An explanation of these measures is also included below under the heading 'Non-GAAP Financial Measures.' Webcast and Conference Call Information Pulse Biosciences' management will host a conference call today, August 12, 2025, beginning at 1:30pm PT. Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 or 1-646-307-1963 and providing passcode 2036874. A live and recorded webcast of the event will be available at About Pulse Biosciences ® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company's proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA, nanosecond PFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries. Non-GAAP Financial Measures In this press release, in order to supplement the Company's condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for the statement of operations. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results in order to supplement investors' and other readers' understanding and assessment of the Company's financial performance. Company management uses these measurements as aids in monitoring the Company's ongoing financial performance from quarter to quarter, and year to year, on a regular basis and for financial and operational decision-making. Non-GAAP adjustments include stock-based compensation, depreciation and amortization, restructuring, severance, and a legal settlement. From time to time in the future, there may be other items that the Company may exclude if the Company believes that doing so is consistent with the goal of providing useful information to management and investors. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. Investors are cautioned that there are a number of limitations associated with the use of non-GAAP financial measures as analytical tools. Investors are encouraged to review these reconciliations, and not to rely on any single financial measure to evaluate the Company's business. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies, which could reduce the usefulness of the Company's non-GAAP financial measures as tools for comparison. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. Non-GAAP financial measures in this earnings release exclude non-cash expenses for stock-based compensation, depreciation and amortization, restructuring costs, severance expense and legal settlement expenses. Forward-Looking Statements All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company's nsPFA technology and CellFX System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning the Company's future commercialization and product development efforts and whether those efforts will be successful, statements concerning early clinical successes and whether they are predictive of the safety and effectiveness of any medical device, such as the nsPFA 360° Cardiac Catheter System, the nsPFA Cardiac Surgical System, and the nsPFA Percutaneous Electrode System, and statements concerning the Company's future clinical and regulatory initiatives anywhere in the world, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences' current expectations, estimates, and projections regarding Pulse Biosciences' business, operations and other similar or related factors. Words such as 'may,' 'will,' 'could,' 'would,' 'should,' 'anticipate,' 'predict,' 'potential,' 'continue,' 'expects,' 'intends,' 'plans,' 'projects,' 'believes,' 'estimates,' and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences' control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences' filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available. PULSE BIOSCIENCES, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except per share amounts) (Unaudited) Three-Month Periods Ended Six-Month Periods Ended June 30, June 30, 2025 2024 2025 2024 Revenues: Product revenues $ — $ — $ — $ — Total revenues — — — — Cost and expenses: Research and development 12,088 7,230 22,401 13,971 General and administrative 8,187 4,496 15,918 8,370 Total cost and expenses 20,275 11,726 38,319 22,341 Loss from operations (20,275 ) (11,726 ) (38,319 ) (22,341 ) Other income: Interest income, net 1,107 343 2,356 821 Total other income 1,107 343 2,356 821 Net loss (19,168 ) (11,383 ) (35,963 ) (21,520 ) Comprehensive loss $ (19,168 ) $ (11,383 ) $ (35,963 ) $ (21,520 ) Net loss per share: Basic and diluted net loss per share $ (0.28 ) $ (0.20 ) $ (0.54 ) $ (0.38 ) Weighted average shares used to compute net loss per common share — basic and diluted 67,276 57,180 67,201 57,152 Expand Reconciliation of GAAP to Non-GAAP Financial Measures The following table presents the reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures: (In thousands) (Unaudited) Three-Month Periods Ended Six-Month Periods Ended June 30, June 30, 2025 2024 2025 2024 Reconciliation of GAAP to non-GAAP Research and development: GAAP Research and development $ 12,088 $ 7,230 $ 22,401 $ 13,971 Less: Stock-based compensation expense (2,335 ) (1,001 ) (5,097 ) (1,950 ) Less: Depreciation and amortization (44 ) (52 ) (90 ) (105 ) Non-GAAP Research and development $ 9,709 $ 6,177 $ 17,214 $ 11,916 Reconciliation of GAAP to non-GAAP General and administrative: GAAP General and administrative $ 8,187 $ 4,496 $ 15,918 $ 8,370 Less: Stock-based compensation expense (2,854 ) (1,051 ) (5,773 ) (1,861 ) Less: Depreciation and amortization (229 ) (246 ) (466 ) (492 ) Add: Legal settlement — — 590 — Non-GAAP General and administrative $ 5,104 $ 3,199 $ 10,269 $ 6,017 Reconciliation of GAAP to non-GAAP Cost and expenses: GAAP Cost and expenses $ 20,275 $ 11,726 $ 38,319 $ 22,341 Less: Stock-based compensation expense (5,189 ) (2,052 ) (10,870 ) (3,811 ) Less: Depreciation and amortization (273 ) (298 ) (556 ) (597 ) Add: Legal settlement — — 590 — Non-GAAP Cost and expenses $ 14,813 $ 9,376 $ 27,483 $ 17,933 Reconciliation of GAAP to non-GAAP Net loss: GAAP Net loss $ (19,168 ) $ (11,383 ) $ (35,963 ) $ (21,520 ) Add: Stock-based compensation expense 5,189 2,052 10,870 3,811 Add: Depreciation and amortization 273 298 556 597 Less: Legal settlement — — (590 ) — Non-GAAP Net loss $ (13,706 ) $ (9,033 ) $ (25,127 ) $ (17,112 ) Expand
Business Wire
3 hours ago
- Business Wire
Industry Leader in Lyophilization, Dr. Serguei Tchessalov, Partners with BioTechnique ® to Enhance Customer Capabilities
YORK, Pa.--(BUSINESS WIRE)--BioTechnique ® LLC ('BioTechnique' or the 'Company') proudly welcomes Dr. Serguei Tchessalov, a globally recognized subject matter expert in lyophilization, whose decades of experience in formulation development, process design, and scale-up bring invaluable insight to clients navigating complex biologic and vaccine manufacturing. With over 40 years of experience spanning both Russia and the United States, Dr. Tchessalov brings deep expertise in the formulation and freeze-drying of bacterial, viral, and mRNA-based vaccines, proteins, and other complex biologics. He holds a Ph.D. in Biotechnology Engineering from the Institute of Applied Biochemistry in Moscow, where his research focused on novel formulation and process control methods for lyophilization. After completing postdoctoral training with Professor Michael Pikal at the University of Connecticut, he went on to hold roles at Immunex, Wyeth, and Pfizer, contributing to industry-leading development efforts. Dr. Tchessalov is the founder of SN Lyophilization, a consulting firm dedicated to freeze-drying and parenteral drug product processing. With over 30 scientific publications to his name, his current work focuses on lyophilization scale-up and transfer, as well as processing operations including filtration, filling, freezing, and thawing. His partnership with BioTechnique strengthens the company's ability to support clients with practical, science-driven solutions across the entire drug product lifecycle. BioTechnique ® 's Lyophilization Capabilities At BioTechnique ®, lyophilization is a core competency backed by robust infrastructure and scientific expertise. Our state-of-the-art, aseptic manufacturing facility is equipped to support both clinical and commercial-scale freeze-drying of biologics, including monoclonal antibodies, peptides, vaccines, and other sensitive drug products. We offer flexible lyophilizer configurations, precise cycle development, and seamless tech transfer—all executed under strict cGMP conditions. Whether clients require formulation support, cycle optimization, troubleshooting, or full-process development, BioTechnique provides tailored solutions that prioritize product stability, yield, and regulatory compliance. With Dr. Tchessalov's guidance, our clients gain not only access to advanced modeling tools and industry best practices, but also the strategic insight needed to successfully navigate the complexities of lyophilization from early development through commercialization. For more information on BioTechnique's capabilities, visit
